AmpliChip CYP450 Test: personalized medicine has arrived in psychiatry

References

• Harper CC, Philip R, Rabinowitz M, Gutman SI. FDA perspectives in genetic testing. Expert Rev. Mol. Diagn.5, 643–648 (2005).
   PubMed Web of Science ®Google Scholar
• Cappell K, Arndt M, Carey J. Drugs get smart. Business Week5, 76–85 (2005).
   Google Scholar
• Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functionary diversity. Pharmacogenomics J.5, 6–13 (2005).
   PubMed Web of Science ®Google Scholar
• Madan A, Graham RA, Carroll KM et al. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab. Dispos.31, 421–431 (2003).
   PubMed Web of Science ®Google Scholar
• de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for using pharmacogenetic testing of CYP450 2D6 and CYP450 2C19 in psychiatry. Psychosomatics47, 75–85 (2006).
   PubMed Web of Science ®Google Scholar
• Chou WH, Yan FX, Robbins-Weilert DK et al. Comparison of two CYP2D6 genotyping methods and assessments of genotype–phenotype relationships. Clin. Chem.49, 542–551 (2003).
   PubMed Web of Science ®Google Scholar
• Roche Molecular Systems, Inc.AmpliChip CYP450 Test for In Vitro Diagnostic Use. Roche Molecular Systems, Inc., NJ, USA (2005).
   Google Scholar
• Kirchheiner J, Nickchen K, Bauer M et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry9, 442–473 (2004).
   PubMed Web of Science ®Google Scholar
• Koch WH. Technology platforms for pharmacogenomic diagnostic assays. Nature Rev. Drug Discov.3, 749–761 (2004).
   PubMed Web of Science ®Google Scholar
• Cai WM, Nikoloff DM, Pan RM et al. CYP2D6 genetic variations in healthy adults in psychiatric African–American subjects: implications for clinical practice and genetic testing. Pharmacogenomics J. (2006) (In Press).
   PubMedGoogle Scholar
• Wedlund PJ. The CYP2C19 enzyme polymorphism. Pharmacology6, 174–185 (2000).
   Google Scholar
• de Leon J, Susce MT, Murray-Carmichael E. The AmpliChip CYP450 genotyping test: integrating a new clinical tool. Mol. Diagn. Ther. (2006) (In Press).
   PubMedGoogle Scholar
• Koch WH, Wu L. Genotyping of polymorphic CYP450 genes using the AmpliChip CYP450 test. In: Pharmacogenomics and Proteomics: Enabling the Practice of Personalized Medicine. Wong SHY, Linder MW, Valdes R Jr (Eds), AACC Press, DC, USA (2006) (In Press).
   Google Scholar
• The Medical Letter. AmpliChip CYP450 Test. Med. Lett. Drugs Ther.47(1215–1216), 71–72 (2005).
   Google Scholar
• Greenhalgh T. Papers that report diagnostic or screening tests. Br. Med. J.315, 540–543, (1997).
   PubMed Web of Science ®Google Scholar
• Wu L, Williams M, Koch W. Clinical applications of microarray-based diagnostics tests. Biotechniques39, 577–582 (2005).
   PubMedGoogle Scholar
• Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics3, 229–243 (2002).
   PubMed Web of Science ®Google Scholar
• Luo HR, Gaedigk A, Aloumanis V, Wan YJY. Identification of CYP2D6 impaired functional alleles in Mexican–Americans. Eur. J. Clin. Pharmacol.61, 797–802 (2005).
   PubMed Web of Science ®Google Scholar
• Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Ann. Rev. Pharmacol. Toxicol.41, 815–850 (2001).
   PubMed Web of Science ®Google Scholar
• Gaedigk A, Bradford LD, Marcucci KA et al. Unique CYP2D6 activity distribution and genotype–phenotype discordance in black Americans. Clin. Pharmacol. Ther.72, 76–89 (2002).
   PubMed Web of Science ®Google Scholar
• Gaedigk A, Bradford LD, Alander SW, Leeder JS. CYP2D6*36 gene arrangements within the CYP2D6 locus: association of CYP2D6*36 with poor metabolizer status. Drug Metab. Dispos.34(4), 563–569 (2006).
   PubMed Web of Science ®Google Scholar
• Wennerholm A, Dandara C, Sayi J et al. The African-specific CYP2D6*17 allele encodes an enzyme with changed substrate specificity. Clin. Pharmacol. Ther.71, 77–88 (2002).
   PubMed Web of Science ®Google Scholar
• Lovlie R, Daly AK, Matre GE, Molven A, Steen VM. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? Pharmacogenetics11, 45–55 (2001).
   PubMedGoogle Scholar
• de Leon J, Susce MT, Pan R-M et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J. Clin. Psychiatry66, 15–27 (2005).
   PubMed Web of Science ®Google Scholar
• Ruaño G, Makowski G, Windemuth A et al. High carrier prevalence of deficient and null alleles of CYP2 genes in a major USA hospital: implications for personalized drug safety. Personalized Med.3(2), 131–137 (2006).
   PubMedGoogle Scholar
• Gordon J, Merante F, Weiss SM et al. Pharmacogenetic P450 screening using the Tag-It™ universal bead-based array platform. In: Pharmacogenomics and Proteomics: Enabling the Practice of Personalized Medicine. Wong SHY, Linder MW, Valdes R Jr (Eds), AACC Press, DC (2006) (In Press).
   Google Scholar
• Neville M, Selzer R, Aizenstein B et al. Characterization of cytochrome P450 2D6 alleles using the Invader technology. Biotechniques32, S34–S43 (2002).
   PubMedGoogle Scholar
• Söderbäck E, Zackrisson AL, Lindblom L, Alderborn A. Determination of CYP2D6 gene copy number by pyrosequencing. Clin. Chem.51, 522–531 (2005).
   PubMed Web of Science ®Google Scholar
• Dorado P, Caceres MC, Pozo-Guisado E, Wong ML, Licinio J, Llerena A. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use. Biotechniques39, 571–574 (2005).
   PubMed Web of Science ®Google Scholar
• Ruaño G. Quo vadis personalized medicine. Personalized Med.1, 1–7 (2004).
   PubMedGoogle Scholar
• Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J. Am. Pharm. Assoc.41, 192–199 (2001).
   Google Scholar
• Chou WH, Yan FX, de Leon J et al. An extension of a pilot study: impact from the cytochrome P450-2D6 (CYP2D6) polymorphism on outcome and costs in severe mental illness. J. Clin. Psychopharmacol.20, 246–251 (2000).
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Eng. J. Med.353, 1209–1223 (2005).
   PubMed Web of Science ®Google Scholar
• Roses AD. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nature Rev. Genet.5, 645–656 (2004).
   PubMed Web of Science ®Google Scholar
• Emens LA. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. Am. J. Ther.12, 243–253 (2005).
   PubMedGoogle Scholar
• Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther.77, 1–16 (2005).
   PubMed Web of Science ®Google Scholar
• Corominas H, Baiget M. Clinical utility of thiopurine S-methyltransferase genotyping. Am. J. Pharmacogenomics4, 1–8 (2004).
   PubMedGoogle Scholar
• Weinshilboum R, Wang L. Pharmacogenomics: bench to bedside. Nature Rev. Drug Discov.3, 739–748 (2004).
   PubMed Web of Science ®Google Scholar
• Danzon P, Towse A. The economics of gene therapy and of pharmacogenetics. Value Health5, 5–13 (2002).
   PubMed Web of Science ®Google Scholar
• Wedlund PJ, de Leon J. Pharmacogenetic testing: the cost factor. Pharmacogenomics J.1, 171–174 (2001).
   PubMedGoogle Scholar